AstraZeneca Defends Pulmicort Patents At Fed. Circ.

Law360, New York (August 12, 2013, 4:31 PM EDT) -- AstraZeneca PLC on Monday asked the Federal Circuit to block four generic-drug makers from launching no-name versions of its Pulmicort Respules pediatric asthma medication, saying a lower court relied too heavily on expert testimony in finding one of its patents as obvious and anticipated.

AstraZeneca’s attorney Christopher N. Sipes told a three-judge panel at oral arguments on Monday that New Jersey U.S. District Judge Renee Marie Bumb improperly combined a prior art article of a defendant expert with that same expert's witness testimony to invalidate a...
To view the full article, register now.